Where Science and Nature Evolve™
NeXtGen™ Biologics is on a quest to harness nature's most powerful regenerative blueprint—the extraordinary biology of the axolotl—to develop versatile platform technologies that transcend traditional medical boundaries. Starting with advanced wound care as our proving ground, we're building systems designed to adapt and evolve across therapeutic domains. Where nature has already solved the hardest problems in healing, we strive to decode those solutions and make them clinically viable. Wound care is just the beginning.
Our Patents
NextGen Biologics, Inc., is the owner of the below listed United States and Foreign Patents, Patent Applications, and Registered Trademarks:
| Patent # | Title | Description | Country |
|---|---|---|---|
| US 10,617.790' | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | U.S. |
| US 11,660,376 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | U.S. |
| US 12,311,079 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | U.S. |
| JP 6606429 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | Japan |
| EP 2943209 (FR, DE, & GB) |
Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | EU (GB, DE, FR) |
| IL 239828 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | Israel |
| CN 105246495 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | China |
| KR 10-2284982 | Decellularized Biomaterial from Non-mammalian Tissue | Issued Patent | Korea |
| CA 2897662 | Biomaterial from Non-mammalian Tissue | Issued Patent | Canada |
| Pending | |||
| USSN 16/801,956 | Biomaterial from Non-mammalian Tissue | Pending US Application | U.S. |
| Expired | |||
| WO2014110269 | Decellularized Biomaterial from Non-mammalian Tissue | Expired PCT | International |
| US61/750,555 | Decellularized Biomaterial from Non-mammalian Tissue | Expired provisional | Expired provisional application |
| Trademarks | |||
| 5449020 | NEOMATRIX® | Standard Character Mark | U.S. |
1 Pursuant to 35 USC 287, public and free access to this information constitutes public notice of the existence of US Patent No. 10,617,790.
Interested in Investing?
We’re taking private placement investments.
Contact us to learn more
NeoMatriX® is an unprecedented product in the wound care space
Utilizing the extra-cellular matrix of the axolotl, NeoMatriX® is unlike any other wound matrix on the market.
Wanna stay Updated?
Follow us on LinkedIn and Twitter
There’s a New Skin in the Game™
NextGen Biologics is built on a platform technology designed to adapt, expand, and evolve. Our first clinical focus—advanced wound care—is simply the proving ground. What drives us goes deeper: the extraordinary biology of the axolotl, a creature that can regenerate not just limbs, but spinal cord, heart, and brain tissue. We’re not claiming those abilities for ourselves—but when nature demonstrates that kind of regenerative code, we believe it’s worth asking what might be possible if we learn to translate it.
We don’t see the future of medicine in one-off products. We see it in systems—versatile, biology-informed platforms that can be applied across therapeutic domains. That’s the framework guiding our research. Nature has already solved many of the hardest problems in healing; our job is to decode those solutions and render them usable. Wound care was the right place to begin. But it is only the beginning.